Voiding difficulties
Peer reviewed by Prof Cathy Jackson, MRCGPLast updated by Dr Colin Tidy, MRCGPLast updated 22 Jul 2014
Erfüllt die Anforderungen des Patienten redaktionelle Richtlinien
- HerunterladenHerunterladen
- Teilen Sie
Teilen Sie
Diese Seite ist archiviert worden.
Sie wurde in letzter Zeit nicht überarbeitet und ist nicht auf dem neuesten Stand. Externe Links und Verweise funktionieren möglicherweise nicht mehr.
Medizinisches Fachpersonal
Professionelle Referenzartikel sind für Angehörige der Gesundheitsberufe bestimmt. Sie wurden von britischen Ärzten verfasst und basieren auf Forschungsergebnissen, britischen und europäischen Leitlinien. Vielleicht finden Sie den Artikel Symptome des unteren Harntrakts bei Männern oder einen unserer anderen Gesundheitsartikel nützlicher.
In diesem Artikel:
See also the separate articles on Chronic Urinary Retention, Acute Urinary Retention, Urinary Incontinence, Detrusor Instability and Irritable Bladder, Nocturia, Urinary Tract Obstruction, Urinary Tract Infection in Adults, Recurrent Urinary Tract Infection, Lower Urinary Tract Symptoms in Men, Lower Urinary Tract Symptoms in Women.
Urinary continence and micturition are functions which require:
The integrity of the organs (bladder, urethra, and voluntary and involuntary sphincters).
The integrity of the neural pathways responsible for micturition (parasympathetic), continence (sympathetic), and their control and co-ordination.
Apart from the incontinence associated with vesicovaginal fistulae in women, or overflow incontinence associated with a distended bladder in chronic retention, the three principal clinical forms of incontinence are:
Stress incontinence.
Urge incontinence.
Mixed incontinence - combining the two mechanisms.
Voiding difficulties causing discomfort on urination, or retention (chronic or acute), are the reflection of an imbalance between bladder contraction and urethral resistance. The complete list includes the following problems:
Stress incontinence.
Urge incontinence.
Poor flow.
Intermittent stream.
Unvollständige Entleerung.
Straining to void.
Zögern.
Acute retention.
Chronic retention.
Überlaufinkontinenz.
Urinary tract infection (UTI) from residual urine.
Lesen Sie unten weiter
Ätiologie
Zentrales Nervensystem (ZNS)
May be from:
Suprapontine lesions - eg, a cerebrovascular event.
Cord lesions - eg, cord injury, multiple sclerosis.
Peripheral nerve - eg, prolapsed disc, diabetic or other neuropathy.
Reflex due to pain - eg with herpes infections.
Drogen
Especially epidural anaesthesia.
Tricyclics, anticholinergics.
Obstruktion
Prostata-Hypertrophie.
Early oedema after bladder neck repair.
Uterine prolapse, retroverted gravid uterus, fibroids.
Eierstockzysten.
Urethral foreign body, ectopic ureterocele.
Bladder polyp or cancer.
Bladder overdistension
After epidural for childbirth.
Faecal impaction is a cause of retention with overflow.
Where detrusor weakness is the cause, there is incomplete bladder emptying with dribbling overflow incontinence.
Nachforschungen
Mid-stream specimen of urine (MSU) should always be taken to exclude infection.
Ultrasound should be performed for residual urine and bladder wall thickness (>6 mm on transvaginal scan associated with detrusor instability).
Cystourethroscopy is also recommended.
Uroflowmetry - a rate of <15 mL/second for a volume of >150 mL is abnormal. This test should be performed before any surgery is contemplated.
Urodynamic studies; subtraction cystometry is a subtraction of intra-abdominal pressure from measured intravesical pressure to give detrusor pressure. Intravesical measure is a mix of bladder pressure and intra-abdominal pressure.
Lesen Sie unten weiter
Verwaltung
This will depend on the cause. See links to separate articles above for more detail.
Detrusor instability
Avoid caffeine (mild diuretic, detrusor stimulant).
Begin bladder training to increase the interval between voiding.
Anticholinergic drugs are effective - eg, oxybutynin; however there may be problems with compliance:12
Start with 2.5 mg/12-hourly, increasing slowly up to 5 mg/6-hourly (per 12 hours if elderly).
Side-effects include dry mouth, blurred vision, nausea, headache, constipation, diarrhoea and abdominal pain. These are less if modified-release once-daily tablets are used.
30 mg/day of Ditropan XL® may be tolerated (approach this by weekly 5 mg jumps). Tolterodine (eg, 2 mg/12-hourly) is also effective, with a lower side-effect profile.
In the majority of cases this is successful, but in those where it is not, intravesical therapies have been introduced (eg, neuromodulation) and alternative drug therapies (eg, vanilloids, botulinum toxin injection), and surgery.3
Stress incontinence4
Pelvic floor muscle physiotherapy may help those with symptoms.
Although surgery is commonly performed to alleviate or cure stress incontinence, there are non-surgical options that might well be explored and tried before a woman undergoes surgery.5
Minimally invasive techniques (eg, tension-free tape) have been shown to be effective and acceptable to the patient.6
The least drastic treatments are behavioural therapies, chiefly pelvic floor muscle training - Kegel exercises. This method is effective but has the drawback of poor patient compliance.
Medical management has included hormone replacement therapy and alpha-adrenergic agonists, but questionable results and intolerable risks have shifted this mode to serotonin-norepinephrine reuptake inhibitors, which have CNS action.
Finally, there are urethral occlusive devices, which have poor acceptance owing to side-effects and difficulty of use.
Nykturie
See the separate article on Nocturia.
Acute retention
This may require catheterisation. A suprapubic catheter should be sited if the catheter will be needed for several days.
For persistent conditions (eg, neurological conditions), self-catheterisation techniques may be learned (eg, with a LoFric® gel-coated catheter).
With detrusor weakness, drugs may relax the urethral sphincter or stimulate the detrusor muscle.
Alpha-blockers (eg, tamsulosin 400 micrograms/24-hourly) relax the bladder neck; diazepam relaxes the sphincter.
Obstructive causes
Operative measures may overcome some of the obstructive causes (eg, urethrotomy for distal urethral stenosis) but this is uncommon.
In approximately one half of women, the causes of obstructive voiding dysfunction are previous anti-incontinence surgery and pelvic organ prolapse, which will usually lead to a surgical intervention.
For men, benign prostate disease is by far the most common cause of obstructive voiding.
Recurrent UTI
This is defined as three episodes in 12 months.
It may benefit from antibiotic prophylaxis. However, there is little evidence to support continuous rather than postcoital dosing.7 There is no evidence that rate of recurrence is affected once prophylaxis has stopped.
Topical oestrogens offer some benefit over placebo in postmenopausal women.8
Cranberry juice may be beneficial in prevention but the evidence is not clear.9
Weiterführende Literatur und Referenzen
- Costantini E, Lazzeri M, Porena M; Hysterectomy and stress urinary incontinence. Lancet. 2008 Feb 2;371(9610):383; author reply 383-4.
- Nabi G, Cody JD, Ellis G, et alAnticholinergika im Vergleich zu Placebo zur Behandlung des Syndroms der überaktiven Blase bei Erwachsenen. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003781.
- Roxburgh C, Cook J, Dublin N; Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003190.
- Freeman RM, Adekanmi OA; Overactive bladder. Best Pract Res Clin Obstet Gynaecol. 2005 Dec;19(6):829-41. Epub 2005 Sep 19.
- Urinary incontinence in women: management; NICE Clinical Guideline (September 2013 - last updated November 2015)
- Appell RA, Davila GW; Treatment options for patients with suboptimal response to surgery for stress urinary incontinence. Curr Med Res Opin. 2007 Feb;23(2):285-92.
- Sassani P, Aboseif SR; Stress urinary incontinence in women. Curr Urol Rep. 2009 Sep;10(5):333-7.
- Albert X, Huertas I, Pereiro II, et al; Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004;(3):CD001209.
- Perrotta C, Aznar M, Mejia R, et al; Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005131.
- Jepson RG, Williams G, Craig JCCranberries zur Prävention von Harnwegsinfektionen. Cochrane Database Syst Rev. 2012 Oct 17;10:CD001321. doi: 10.1002/14651858.CD001321.pub5.
Lesen Sie unten weiter
Artikel Geschichte
Die Informationen auf dieser Seite wurden von qualifizierten Klinikern verfasst und von Fachleuten geprüft.
22 Jul 2014 | Latest version

Fragen, teilen, verbinden.
Stöbern Sie in Diskussionen, stellen Sie Fragen, und tauschen Sie Erfahrungen zu Hunderten von Gesundheitsthemen aus.

Fühlen Sie sich unwohl?
Beurteilen Sie Ihre Symptome online und kostenlos